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Background: To find candidate genes for a predictive chemosensi-
tivity test in patients with lung cancer by using a literature review.
Methods: Using MEDLINE searches, “in vitro chemosensitivity
associated genes” and articles on association of the gene alteration
with clinical chemosensitivity in lung cancer patients were selected.
We calculated odds ratios (ORs) and their 95% confidence intervals
(95% CIs) of response rates for patients who had tumors with or
without gene alteration. Combined ORs and 95% CIs were estimated
using the DerSimonian-Laird method.
Results: Of the 80 in vitro chemosensitivity-associated genes iden-
tified, 13 genes were evaluated for association with clinical chemo-
sensitivity in 27 studies. The median (range) number of patients in
each study was 50 (range, 28-108). The response rates of lung
cancer with high and low P-glycoprotein expression were 0% and
73% to 85%, respectively (p  0.001). Glutathione S-transferase pi
expression (OR 0.22, 95% CI 0.06-0.79), excision repair cross-
complementing 1 alterations (combined OR 0.53, 95% CI 0.28-1.01;
p 0.055), and tumor suppressor p53 mutation (combined OR 0.25,
95% CI 0.12-0.52) were associated with clinical chemosensitivity.
Conclusion: In total, 80 in vitro chemosensitivity-associated genes
were identified in the literature, and high and low P-glycoprotein,
glutathione S-transferase pi expression, excision repair cross-com-
plementing 1 alterations, and tumor suppressor p53 mutation were
candidates for future clinical trials of chemosensitivity tests in lung
cancer patients.
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(J Thorac Oncol. 2006;1: 31–37)
Lung cancer is the leading cause of death in many countriesdespite extensive basic research and clinical trials. Ap-
proximately 80% of patients with lung cancer have developed
distant metastases either by the time of initial diagnosis or
during recurrence after surgery for local disease. Systemic
chemotherapy against lung cancer, however, has limitations
in efficacy such that patients with distant metastases rarely
live long.1
Tumor response to chemotherapy varies among pa-
tients, and objective tumor response rates to standard chemo-
therapy regimens are approximately 20 to 40% in patients
with non—small-cell lung cancer and 60 to 90% in patients
with small-cell lung cancer. Thus, it would be extremely
useful to know in advance whether patients have tumors that
respond to chemotherapy agents and whether the tumors
would be resistant to such therapy. For this purpose, cell
culture-based chemosensitivity tests have been investigated
for more than 20 years, but they are not widely accepted
because of technical problems such as the large amount of
material required, a low success rate for the primary culture,
length of time required, and poor correlation with the clinical
response.2–5
To overcome these obstacles, DNA-, RNA-, and pro-
tein-based chemosensitivity tests have been created, but gene
alterations that are predictive of the clinical drug response are
not established. Recently, as many as 400 genes whose
expression was associated with drug response were identified
by cDNA microarray studies, but their functions do not seem
to be related to drug sensitivity or resistance.6–10 In addition,
the genes identified by microarray studies were highly unsta-
ble and depended on the selection of patients used for gene
identification.11,12 The purpose of this study was to provide an
overview of gene alterations in lung cancer that are associated
with chemotherapy drug response to identify candidate genes
for predictive chemosensitivity tests in patients with lung
cancer.
MATERIALS AND METHODS
Because one set of genes associated with chemosensi-
tivity is those directly involved in drug resistance mecha-
nisms, we conducted a MEDLINE search for articles on
tumor drug resistance published in the years 2001–2003. This
search yielded 112 studies, including several review articles.
By searching manually through these articles, we identified
134 genes or gene families that may be involved in drug
resistance based on their function. We conducted the second
MEDLINE searches for papers of in vitro studies on the 134
genes or gene families by using their names as a keyword.
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From the 134 genes, we selected genes that met the following
definition of “in vitro chemosensitivity associated genes”: 1)
alteration of the gene was identified in a human drug-induced
resistant, solid tumor cell line; 2) transfection of the gene
induced drug resistance; or 3) down-regulation of the gene or
its encode protein increased drug sensitivity. In this latter
category, we included studies in which the gene expression or
function was suppressed by antisense RNA, hammerhead
ribozyme, or an antibody against the gene product. We
excluded studies in which drugs were used to inhibit function
because the specificity of the drug against the target may not
have been complete. We performed a third MEDLINE search
for articles on the association between the gene alteration and
chemosensitivity of lung cancer cell lines by using the name
of the gene as a keyword. Articles in which the association
was evaluated in 20 or more cell lines were included in this
study. Finally, we searched MEDLINE for studies on the
association between the gene alteration and clinical drug
response in patients with lung cancer by using the name of the
gene as a keyword. Articles in which the association was
evaluated in 25 or more patients with advanced lung cancer
were included in this study. Studies in which gene expression
was evaluated with microarray were excluded because result
analysis and interpretation of this technique have not been
established, as indicated by the fact that the list of genes
identified by microarray studies was highly variable without
overlap between these gene sets.11,12 Clinical studies on
concurrent chemoradiotherapy were excluded. We con-
structed 2  2 tables from the response data and calculated
odds ratios (ORs), their variances, and 95% confidence inter-
vals (95% CIs) for the patients who had tumors with gene
alteration relative to those who had tumors without gene
alteration. Combined ORs and 95% CIs were estimated using
the DerSimonian-Laird method.13 When a response rate was
0, association with gene alteration was evaluated using the 2
test because 95% CIs for ORs cannot be calculated. The name
of each gene was standardized according to Human Gene
Nomenclature Database of National Center for Biotechnol-
ogy Information.
RESULTS
Of the 134 genes or gene families found, a gene
alteration in drug-induced resistant cells, an increased or
decreased resistance in transfected cells, and an altered sen-
sitivity in gene down-regulated cells were reported for 45, 57,
and 32 genes, respectively. In total, 80 genes met the defini-
tion of “in vitro chemosensitivity associated gene” (Table 1).
Gene alteration was associated with in vitro chemosen-
sitivity in 15 (50%) of 30 studies on 15 (56%) of 27 gene
alterations (Table 2). Clinical drug response was evaluated in 27
studies on 13 gene alterations. The methods used to identify
gene alteration included immunohistochemical protein expres-
sion analysis (n  18), polymerase chain reaction (PCR)-
based mRNA expression analysis (n  3), and PCR-based
mutation analysis (n  6). All but one clinical study was
retrospective, and the median (range) number of patients in
each study was 50 (28-108). Gene alteration was associated
with clinical response in 8 of the 27 (30%) studies (Table 2).
We evaluated the association between transporter P-
glycoprotein/multidrug resistance 1 (ABCB1) expression and
clinical chemosensitivity in four studies. The response rate of
lung cancer with high ABCB1 expression was consistently
0%, whereas that for lung cancer with low ABCB1 expres-
sion was 73 to 85% (Table 3). Among drug targets, only
topoisomerase II-beta (TOP2B) expression was associated
with clinical drug response in patients with small-cell lung
cancer (OR 0.29, 95% CI 0.09-0.95). The intracellular detox-
ifier glutathione s-transferase pi (GSTP1) was associated with
both in vitro and clinical drug response (OR 0.22, 95% CI
0.06-0.79) (Table 4). DNA repair gene excision repair cross-
complementing 1 (ERCC1) alterations were associated with
drug response among patients with non—small-cell lung
cancer with marginal statistical significance; the combined
OR (95% CI) for ERCC1 alteration was 0.53 (0.28-1.01; p 
0.055) (Table 5). Tumor suppressor p53 (TP53) mutation was
the only alteration associated with drug response among
patients with non—small-cell lung cancer among genes in-
volved in cell cycle and apoptosis. A combined OR (95% CI)
for TP53 among patients with non—small-cell lung cancer
was 0.25 (0.12-0.52) (Table 6). B-cell CLL/lymphoma 2
(BCL2) and its family protein expression was not associated
with clinical drug response (Table 7).
DISCUSSION
We identified 80 in vitro chemosensitivity-associated
genes in our literature search. Of these, 13 were evaluated
clinically in 27 studies; ABCB1, TOP2B, GSTP1, and
ERCC1 expression and TP53 mutation were associated with
changes to drug responses among patients with lung cancer.
Classical drug resistance is believed to be the result of
molecular changes inhibiting the drug-target interaction.
ABCB1, an ATP-binding cassette protein, acts as an energy-
dependent transmembrane efflux pump and decreases the
intracellular accumulation of anticancer drugs, including an-
thracyclines, vinca alkaloids, taxanes, and epipodophyllotox-
TABLE 1. In Vitro Chemosensitivity-Associated Genes
Transporters: ABCA2, ABCB1, ABCB11, ABCC1, ABCC2, ABCC3,
ABCC4, ABCC5, ABCG2, MVP, ATP7A, ATP7B, SLC29A1,
SLC28A1, SLC19A1
Drug targets: TUBB, TUBB4, TUBA, TYMS, TOP1, TOP2A, TOP2B,
DHFR,
Target-associated proteins : MAP4, MAP7, STMN1, KIF5B, HSPA5,
PSMD14, FPGS
Intracellular detoxifiers: GSTP1, GPX, GCLC, GGT2, MT, RRM2,
AKR1B1
DNA damage recognition and repair proteins: HMGB1, HMGB2, ERCC1,
XPA, XPD, MSH2, MLH1, PMS2, APEX1, MGMT, BRCA1, GLO1
Cell cycle regulators: RB1, GML, CDKN1A, CCND1, CDKN2A,
CDKN1B
Mitogenic signal regulators: ERBB2, EGFR, KRAS2, HRAS, RAF1
Survival signal regulators: AKT1, AKT2
Integrin: ITGB1
Transcription factors: JUN, FOS, MYC, NFKB1
Apoptosis regulators: TP53, MDM2, TP73, BCL2, BCL2L1, MCL1,
BAX, BIRC4, BIRC5, TNFRSF6, CASP3, CASP8, HSPB1
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ins. Overexpression of this protein gives tumor cells a mul-
tidrug resistance phenotype in vitro, which is thought to be
associated with clinical chemoresistance.14 Our review
showed that the response rate of tumors with ABCB1 over-
expression was 0 in all studies of lung cancer, whereas that
for lung cancer tumors with low ABCB1 expression was 73
to 85% (Table 3).
There is a close relationship between drug sensitivity
and quantitative and qualitative alterations of the drug’s
target, including tamoxifen sensitivity and estrogen receptor
expression and trastuzumab response and Her-2/neu overex-
pression in breast cancer,15 imatinib resistance and BCR-
ABL gene amplification and mutations in Philadelphia chro-
mosome-positive leukemias,16 and imatinib response and KIT
gene mutations in gastrointestinal stromal tumors.17 In all of
these cases, the target molecule is a receptor or a mutated
tyrosine kinase located at the entry of growth-stimulating
signal transduction pathways. Recently, gefitinib, a tyrosine
kinase inhibitor of the epidermal growth factor receptor
(EGFR), has been developed, and two large phase II trials
showed a response rate of 18% and 12% in patients with
non—small-cell lung cancer who were previously treated
with conventional chemotherapy.18,19 Responses to the drug
have been unpredictable, but mutations of the EGFR gene
were identified in patients with gefitinib-responsive lung
cancer.20,21 Furthermore, all mutations in these tumors were
restricted to the activation loop of the kinase domain of
EGFR, which are in distinct contrast to mutations in extra-
celluar and regulatory domains of EGFR in glioblastoma,
which are unresponsive to gefitinib.22 Thus, molecular devel-
opments of structure and function of the targets hold the
promise of targeted cancer therapy. The target molecules of
many anticancer cytotoxic agents have not been clearly de-
fined; therefore, the relationship between the target molecule
status and sensitivity to the agent has not been established.
TOP2B expression was associated with drug response in
patients with small-cell lung cancer, with a response rate of
71% for high TOP2B expression tumors versus 90% for low
TOP2B expression tumors (OR 0.29, 95% CI 0.09-0.95).23
This result, however, is in contrast with the idea that a higher
TABLE 2. Chemosensitivity-Associated Genes and Association with Chemosensitivity
Association with chemosensitivity
In vitro studies (n) Clinical studies (n)
Category No of Genes Total Yes % Total Yes %
Transporter 15 9 5 55 4 4 100
Drug target 8 2 1 50 5 1 20
Target-associated protein 7 0 0 0 0
Intracellular detoxifier 7 3 3 100 1 1 100
DNA repair 10 1 1 100 6 0 0
Damage recognition protein 2 0 0 0 0
Cell cycle 6 4 2 50 2 0 0
Mitogenic signal 5 3 1 33 1 0 0
Survival signal 2 0 0 0 0
Transcription factor 4 3 0 0 0 0
Cell adhesion-mediated 1 0 0 0 0
drug-resistance protein
Apoptosis 13 5 2 40 8 2 25
Total 80 30 15 50 27 8 30
TABLE 3. ABCB1 (P-Glycoprotein) and Clinical Response to Chemotherapy
Author Histology Drugs Method Expression Patients (n) RR (%) Odds ratio
Yeh et al.30 Non-small cell Paclitaxel IHC Low 35 80 0
High 15 0 p  0.001*
Kawasaki et al.31 Small cell CAV or EP IHC Low 26 85 0
High 4 0 p  0.001*
Hsia et al.32 Small cell EP IHC Low 37 73 0
High 13 0 p  0.001*
Savaraj et al.33 Small cell CAV, CEV, or EP RT-PCR Low 24 75 0
High 7 0 p  0.001*
Combined odds ratio for ABCB expression in patients with SCLC: 0
IHC, Immunohistochemical analysis; RR, response rate; RT-PCR, reverse transcriptase-polymerase chain reaction.
*Calculated using the 2 test because the confidence interval cannot be calculated.
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TABLE 4. Drug Targets, Intracellular Detoxifier, and Clinical Response to Chemotherapy
Author Histology Drugs Method Expression Patients (n) RR (%) Odds ratio (95% CI)
Beta-tubulin class III
Rosell et al.34 Non-small cell Paclitaxel, Real-time Low 13 46 0.39
Vinorelbine PCR High 24 25 (0.09-1.62)
Topoisomerase II-alpha
Dingemans et al.23 Small cell CEV or EP IHC Low 65 85 0.65
High 23 80 (0.20-2.17)
Dingemans et al.35 Non-small cell Platinum-based IHC Low 30 47 0.67
High 8 38 (0.14-3.40)
Topoisomerase II-beta
Dingemans et al.23 Small cell CEV or EP IHC Low 48 90 0.29
High 35 71 (0.09-0.95)
Dingemans et al.35 Non-small cell Platinum-based IHC Low 18 50 0.86
High 13 46 (0.21-3.58)
Glutathione s-transferase pi
Nakanishi et al.36 Non-small cell Cisplatin-based IHC Low 17 47 0.22
High 37 16 (0.06-0.79)
CI, confidence interval; IHC, immunohistochemical analysis; PCR, polymerase chain reaction; RR, response rate; CEV, cyclophosphamide, etoposide, and vincristine; EP,
etoposide and cisplatin.
TABLE 5. DNA Repair Genes and Clinical Response to Chemotherapy
Author Histology Drugs Method Alteration Patients (n) RR (%)
Odd ratio
(95% CI)
Excision repair cross-complementing 1
expression
Lord et al. 37 Non-small cell Cisplatin, Real-time Low 23 52 0.38
gemcitabine PCR High 24 36 (0.11-1.26)
Excision repair cross-complementing 1
(ERCC1) polymorphism at codon
118
Ryu et al.38 Non-small cell Cisplatin-based PCR C/C 54 54 0.61
Hybridization C/T or T/T 53 42 (0.28-1.31)
Combined odds ratio (95% C.I.) for
ERCC1 alteration in patients with
NSCLC0.53 (0.28-1.01, p  0.055)
Xeroderma pigmentosum group D
polymorphism
At codon 231
Ryu et al.38 Non-small cell Cisplatin-based PCR G/G 100 48 1.08
Hybridization G/A or A/A 8 50 (0.26-4.57)
At codon 312
Camps et al.39 Non-small cell Cisplatin, PCR G/G 18 17 3.33
gemcitabine Sequencing G/A or A/A 15 40 (0.66-16.7)
At codon 751
Camps et al.39 Non-small cell Cisplatin, PCR A/A 22 23 2.04
gemcitabine Sequencing A/C or C/C 16 38 (0.49-8.45)
Ryu et al.38 Non-small cell Cisplatin-based PCR A/A 96 49 0.74
Hybridization A/C 12 42 (0.22-2.51)
Combined odds ratio (95% CI) for XPD polymorphism in patients with NSCLC: 1.38 (0.68-2.78).
CI, confidence interval; PCR, polymerase chain reaction; RR, response rate; NSCLC, non—small-cell lung cancer; XPD, xeroderma pigmentosum group D.
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expression of topoisomerase II enzymes correlates with
greater chemosensitivity in patients with breast cancer.24
In addition to genes involved in classical drug resis-
tance, genes that act downstream of the initial damage in-
duced by a drug-target complex are thought to play an
important role in chemosensitivity.25 ERCC1 is a key enzyme
in nucleotide excision repair, one of the key pathways by
which cells repair platinum-induced DNA damage. High
levels of ERCC1 mRNA have been associated with platinum
resistance in the treatment of ovarian and gastric cancer.26,27
The codon 118 in exon 4 of ERCC1 gene is polymorphic with
the nucleotide alteration AAC to AAT. Although this base
change results in coding for the same amino acid, it may
affect gene expression based on the usage frequency of
synonymous codons.28 The associations between drug re-
sponse and both ERCC1 gene expression and polymorphism
at codon 118 in patients with non—small-cell lung cancer
have been reported in the literature. A combined OR (95%
TABLE 6. Cell Cycle Regulators, Mitogenic Signals, Tumor Protein p53, and Clinical Response to Chemotherapy
Author Histology Drugs Method Alteration
Patients
(n)
RR
(%)
Odds ratio
(95% CI)
Retinoblastoma 1 expression
Gregorc et al.40 Non-small cell Cisplatin-based IHC Low 61 51 0.45
High 41 32 (0.20-1.03)
Cyclin-dependent kinase inhibitor 1A, p21 expression
Dingemans et al.23 Small cell CEV, EP IHC Low 63 90 0.57
High 22 71 (0.17-1.92)
Kirsten rat sarcoma 2 viral oncogene homolog mutation
Rodenhuis et al. 41, a Aenocarcinoma Ifosfamide, PCR-MSH Normal 46 26 0.65
carboplatin Mutated 16 19 (0.16-2.70)
Tumor protein p53 (P53) mutation
Nakanishi et al.36 Non-small cell Cisplatin-based IHC Normal 11 45 0.19
Mutated 29 15 (0.04-0.94)
Gregorc et al.40 Non-small cell Cisplatin-based IHC Normal 56 57 0.26
Mutated 46 26 (0.11-0.62)
Combined odds ratio (95% CI) for P53 mutation in
patients with NSCLC: 0.25 (0.12-0.52)
Kawasaki et al.31 Small cell CAV or EP IHC Normal 10 70 1.3
Mutated 20 75 (0.24-6.96)
Dingemans et al.23 Small cell CEV or EP IHC Normal 47 85 0.81
Mutated 45 82 (0.27-2.45)
Combined odds ratio (95% C.I.) for P53 mutation
in patients with SCLC: 0.93 (0.37-2.35).
CI, confidence interval; IHC, immunohistochemical analysis; PCR-MSH, polymerase chain reaction-mutation specific hybridization; RR, response rate; CEV, cyclophosphamide,
etoposide, and vincristine; EP, etoposide and cisplatin.
aProspective study.
TABLE 7. B-Cell CLL/Lymphoma 2 (BCL2) Family Expression and Clinical Response to Chemotherapy
Author Histology Drugs Method Expression Patients (n) RR (%)
Odds ratio
(95% CI)
BCL2
Krug et al.42 Non-small cell Docetaxel, IHC Low 26 46 1.75
vinorelbine High 5 60 (0.25-12.3)
Dingemans et al.23 Small cell CEV or EP IHC Low 20 79 1.36
High 71 85 (0.38-4.86)
Takayama et al.43 Small cell CAV or EP IHC Low 17 76 0.50
High 21 62 (0.12-2.08)
Combined odds ratio (95% CI) for BCL2 expression in patients with SCLC: 0.87 (0.33-2.32)
BAX (BCL2-associated X protein)
Krug et al.42 Non-small cell Docetaxel, vinorelbine IHC Low 9 56 0.72
High 19 47 (0.15-3.54)
CI, confidence interval; IHC, immunohistochemical analysis; RR, response rate; CEV, cyclophosphamide, etoposide, and vincristine; EP, etoposide and cisplatin.
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CI) for these ERCC1 alterations was 0.53 (0.28-1.01, p 
0.055), although each study failed to show statistical signif-
icant association. Thus, ERCC1 may be a candidate for
evaluation of the predictability of drug response in future
clinical trials.
TP53, which is mutated or deleted in more than half of
lung cancer cells, has a remarkable number of biological
activities, including cell-cycle checkpoints, DNA repair, ap-
optosis, senescence, and maintenance of genomic integrity.
Because most anticancer cytotoxic agents induce apoptosis
through either DNA damage or microtubule disruption, mu-
tated TP53 may decrease chemosensitivity by inhibiting ap-
optosis or, in contrast, may increase chemosensitivity by
impairing DNA repair after drug-induced DNA damage.29
This review showed that mutated TP53 was associated with
poor drug response in patients with non—small-cell lung
cancer (Table 6).
No other genes located downstream (including xero-
derma pigmentosum group D, retinoblastoma 1, cyclin-de-
pendent kinase inhibitor 1A, Kirsten rat sarcoma 2 viral
oncogene homolog, B-cell CLL/lymphoma 2, and B-cell
CLL/lymphoma 2-associated X protein) were associated with
clinical drug response (Tables 5-7). The association was
evaluated for only 8 of 43 in vitro chemosensitivity-associ-
ated downstream genes; therefore, key genes may be among
the remaining 35 genes. Most clinical studies included a
limited number of patients with various background charac-
teristics such as tumor stage and chemotherapy regimen
administered, which resulted in low statistical power to iden-
tify the association. Finally, because all but one study was
retrospective, the quality of tumor samples may vary, and it
is therefore unclear whether the gene alteration was detected
in all samples. Thus, in future prospective clinical studies, the
method of tumor sample collection and preservation, as well
as immunohistochemistry and polymerase chain reaction-
based methods, should be standardized, and the sample size
of patients should be determined with statistical consider-
ation.
The recently developed microarray technique enables
investigators analyze mRNA expression of more than 20,000
genes at once, and as many as 100 to 400 genes were selected
statistically as chemosensitivity-related genes.6–8,10 Among
them, however, only a limited number of genes were func-
tionally related to chemosensitivity, and only ABCB1 and
BAX corresponded with the 80 chemosensitivity-associated
genes identified in this literature review, which were picked
because of their known function and contribution to in vitro
chemosensitivity. Thus, it will be interesting to evaluate the
role of expression profile of these genes using microarray
analysis.
The association between the expression and alterations
of genes and clinical drug responses should be studied further
in prospective trials. ABCB1, GSTP1, ERCC1, and TP53,
and other genes identified by exploratory microarray analyses
should be evaluated in those trials. Simple methods to iden-
tify gene alterations, such as immunohistochemistry and
polymerase chain reaction-based techniques, will be feasible
in future clinical trials because of their simplicity, cost, and
time. The median number of patients in retrospective studies
analyzed in this review was 50 (range, 28-108). In future
prospective trials, sample size consideration for statistical
power will also be important.
In conclusion, we identified 80 in vitro chemosensitiv-
ity-associated genes in a review of the literature; ABCB1,
GSTP1, and ERCC1 expression and TP53 mutation were
associated with drug responses among patients with lung
cancer.
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